Search - tctmd.com

Displaying 101 - 120 of 154

Sort: Relevancy | Date

What’s Going to Be Hot at ESC 2022?

News Opinion Editor's Corner ESC 2022

What’s Going to Be Hot at ESC 2022?

August 22, 2022

Quadruple Therapy Costs Prohibitive for Many HFrEF Patients

News Daily News

Quadruple Therapy Costs Prohibitive for Many HFrEF Patients

June 21, 2022

SERENADE: No Benefit, Possible Harm With Macitentan in HFpEF and PAH

News Daily News ESC Heart Failure 2022

SERENADE: No Benefit, Possible Harm With Macitentan in HFpEF and PAH

May 22, 2022

The Hunt for Protein Culprits in COVID-19’s Cardiac Complications

News Daily News

The Hunt for Protein Culprits in COVID-19’s Cardiac Complications

Michael O'Riordan

May 06, 2022

METEORIC-HF: Omecamtiv Mecarbil Doesn’t Boost Exercise Capacity in HFrEF

News Conference News ACC 2022

METEORIC-HF: Omecamtiv Mecarbil Doesn’t Boost Exercise Capacity in HFrEF

April 08, 2022

New HF Guidelines Stress Four Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

News Conference News ACC 2022

New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

April 01, 2022

Risk-Based EHR Alert Doesn’t Improve HF Care or Outcomes: REVEAL-HF

News Conference News AHA 2021

Risk-Based EHR Alert Doesn’t Improve HF Care or Outcomes: REVEAL-HF

Michael O'Riordan

November 19, 2021

GUIDE-HF Hints That Hemodynamic-Guided Management Works in HFpEF

News Conference News TCT 2021

GUIDE-HF Hints That Hemodynamic-Guided Management Works in HFpEF

Michael O'Riordan

November 06, 2021

As Amyloidosis Field Explodes, Physicians Need to Spot and Treat

News Daily News

As Amyloidosis Field Explodes, Physicians Need to Spot and Treat

October 20, 2021

Four Pillars, Fast? Rapid Sequencing of HF Drugs Faces an Uphill Battle

News Features

Four Pillars, Fast? Rapid Sequencing of HF Drugs Faces an Uphill Battle

October 08, 2021

Big Impact Anticipated With HFpEF Expansion of Sacubitril/Valsartan Label

News Daily News

Big Impact Anticipated With HFpEF Expansion of Sacubitril/Valsartan Label

September 20, 2021

PRESERVED-HF: Dapagliflozin Improves Symptoms, Physical Limitations in HFpEF

News Conference News HFSA 2021

PRESERVED-HF: Dapagliflozin Improves Symptoms, Physical Limitations in HFpEF

September 13, 2021

In HFrEF, AI Shows Promise For Predicting Beta Blocker Response

News Conference News ESC 2021

In HFrEF, AI Shows Promise For Predicting Beta Blocker Response

Yael L. Maxwell

September 03, 2021

Retracted Over Fraud Concerns, Surgisphere ACE/ARB Study Still Gets Cited

News Daily News

Retracted Over Fraud Concerns, Surgisphere ACE/ARB Study Still Gets Cited

Michael O'Riordan

August 03, 2021

Beta-blocker Withdrawal Boosts Peak VO2 in HFpEF Subset: PRESERVE-HR

News Conference News ESC Heart Failure 2021

Beta-blocker Withdrawal Boosts Peak VO2 in HFpEF Subset: PRESERVE-HR

July 06, 2021

Empagliflozin Succeeds in HFpEF: EMPEROR-Preserved Top-line Results

News Daily News

Empagliflozin Succeeds in HFpEF: EMPEROR-Preserved Top-line Results

July 06, 2021

Less Cancer Among HF Patients Taking Statins, Registry Shows

News Daily News

Less Cancer Among HF Patients Taking Statins, Registry Shows

Michael O'Riordan

June 23, 2021

Sotagliflozin Beneficial Across a Range of Patients, Including HFpEF

News Conference News ACC 2021

Sotagliflozin Beneficial Across a Range of Patients, Including HFpEF

Michael O'Riordan

May 25, 2021

Belly Fat the Biggest Driver of Obesity-Related CVD, Says AHA

News Daily News

Belly Fat the Biggest Driver of Obesity-Related CVD, Says AHA

Michael O'Riordan

April 26, 2021

Hints of Benefit With Levosimendan in Pulmonary Hypertension Due to HFpEF

News Daily News

Hints of Benefit With Levosimendan in Pulmonary Hypertension Due to HFpEF

Michael O'Riordan

April 15, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.